SMALL CELL LUNG CANCER

This study is testing a new combination of drugs for people with a specific type of lung cancer. It's for patients whose non-small cell lung cancer has changed into a more aggressive small-cell type after their first treatment stopped working. The trial will see if adding a new t…

This study is testing whether a combination of four drugs can help control extensive small cell lung cancer after initial treatment. The trial will involve about 31 adults who have not received prior treatment for this advanced cancer stage. Researchers want to see if this mainte…

This study is testing whether a combination of an immunotherapy drug (adebrelimab) and a milder, oral form of chemotherapy (etoposide) can help control advanced small cell lung cancer in older patients or those who are too frail for standard intensive treatments. It aims to see i…

This study is testing a new two-drug combination for people with advanced lung cancer that has worsened after standard treatments. It aims to find a safe and effective dose and see if the drugs can shrink tumors and control the disease. The trial will enroll about 120 adults who …

This early-stage study aims to check the safety of a new drug called ZG006 when given alongside standard immunotherapy drugs for people with extensive small-cell lung cancer. It will involve about 100 adults who have not yet received treatment for this aggressive cancer. The main…

This is the first-ever study in humans of a new drug called DXC014, designed for people with advanced solid tumors like lung cancer, melanoma, and prostate cancer. The main goal is to find a safe dose and understand how the body processes the drug. Researchers will also look for …

This study is testing whether a new medicine called PF-08634404 works better when given with standard chemotherapy for a rare, aggressive form of lung cancer called transformed small cell lung cancer. The trial will enroll 40 adults who haven't received treatment for this specifi…

This clinical trial is testing whether a new drug called SYS6090, when combined with standard chemotherapy or other targeted therapies, is safe and effective for people with advanced lung cancer. The study will enroll about 600 adults with either non-small cell or small cell lung…

This study aims to test the safety and early effectiveness of SKB500 drug combinations in people with extensive-stage small cell lung cancer. It will enroll 80 participants to see how well the treatment controls cancer growth and how long patients live without their disease getti…

This study is testing whether a new experimental drug called ABBV-706 works better than current standard treatments for aggressive small cell lung cancer that has returned or stopped responding to prior therapy. About 531 adults worldwide will receive either the new drug or one o…

This study is testing whether the drug tarlatamab can shrink or control cancer that has spread to the brain in people with small cell lung cancer. It will involve about 34 patients whose brain tumors are not causing symptoms and who have already tried standard chemotherapy. The m…

This study aims to understand how patients with advanced small cell lung cancer respond to treatments in real hospital settings, not clinical trials. Researchers will observe 96 patients receiving standard care to learn which treatments work best and how safe they are in everyday…

This study aims to learn more about how the lung cancer drug tarlatamab works in real-world patients. Researchers will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug. By analyzing these samples, they hope to understand who res…

This study aims to learn about the real-world safety and effectiveness of the immunotherapy drug adebrelimab in people with advanced solid tumors, primarily lung and gastrointestinal cancers. It will observe 300 patients who have already decided with their doctor to receive this …